<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002849" GROUP_ID="TOBACCO" ID="040799071913353636" MERGED_FROM="" MODIFIED="2011-06-22 12:09:46 +0200" MODIFIED_BY="Kate Cahill" NOTES="&lt;p&gt;Updated 1999/3. Synopsis added 2000/3. Split into separate reviews July 2000 for 2000/4 issue. Synopsis redrafted 2000/4 using consumer network original draft.&lt;br&gt;Search updated 27/8/2003, one study added to excluded list but no changes in text&lt;/p&gt;" NOTES_MODIFIED="2011-06-22 10:05:12 +0100" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="6" REVMAN_SUB_VERSION="5.1.2" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="11.0">
<COVER_SHEET MODIFIED="2011-06-22 12:09:46 +0200" MODIFIED_BY="Kate Cahill">
<TITLE>Anxiolytics for smoking cessation</TITLE>
<CONTACT MODIFIED="2011-06-22 12:09:46 +0200" MODIFIED_BY="Kate Cahill"><PERSON ID="19829" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>John</FIRST_NAME><MIDDLE_INITIALS>R</MIDDLE_INITIALS><LAST_NAME>Hughes</LAST_NAME><EMAIL_1>john.hughes@uvm.edu</EMAIL_1><ADDRESS><DEPARTMENT>Dept of Psychiatry</DEPARTMENT><ORGANISATION>University of Vermont</ORGANISATION><ADDRESS_1>UHC Campus, OH3 Stop # 482</ADDRESS_1><ADDRESS_2>1 South Prospect Street</ADDRESS_2><CITY>Burlington</CITY><ZIP>05401</ZIP><REGION>Vermont</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 802 656 9610</PHONE_1><FAX_1>+1 802 847 1446</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2011-06-22 12:09:46 +0200" MODIFIED_BY="Kate Cahill"><PERSON ID="19829" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>John</FIRST_NAME><MIDDLE_INITIALS>R</MIDDLE_INITIALS><LAST_NAME>Hughes</LAST_NAME><EMAIL_1>john.hughes@uvm.edu</EMAIL_1><ADDRESS><DEPARTMENT>Dept of Psychiatry</DEPARTMENT><ORGANISATION>University of Vermont</ORGANISATION><ADDRESS_1>UHC Campus, OH3 Stop # 482</ADDRESS_1><ADDRESS_2>1 South Prospect Street</ADDRESS_2><CITY>Burlington</CITY><ZIP>05401</ZIP><REGION>Vermont</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 802 656 9610</PHONE_1><FAX_1>+1 802 847 1446</FAX_1></ADDRESS></PERSON><PERSON ID="8169" ROLE="AUTHOR"><PREFIX>Mrs</PREFIX><FIRST_NAME>Lindsay</FIRST_NAME><MIDDLE_INITIALS>F</MIDDLE_INITIALS><LAST_NAME>Stead</LAST_NAME><POSITION>Managing Editor</POSITION><EMAIL_1>lindsay.stead@phc.ox.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Primary Care Health Sciences</DEPARTMENT><ORGANISATION>University of Oxford</ORGANISATION><ADDRESS_1>23-38 Hythe Bridge Street</ADDRESS_1><CITY>Oxford</CITY><ZIP>OX1 2ET</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1865 289285</PHONE_1><FAX_1>+44 1865 289287</FAX_1></ADDRESS></PERSON><PERSON ID="7767" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Tim</FIRST_NAME><LAST_NAME>Lancaster</LAST_NAME><POSITION>Co-ordinating Editor,  Cochrane Tobacco Addiction Group</POSITION><EMAIL_1>tim.lancaster@dphpc.ox.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Primary Health Care</DEPARTMENT><ORGANISATION>University of Oxford</ORGANISATION><ADDRESS_1>Rosemary Rue Building</ADDRESS_1><ADDRESS_2>Old Road Campus</ADDRESS_2><CITY>Oxford</CITY><ZIP>OX3 7LF</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1865 289285</PHONE_1><FAX_1>+44 1865 289287</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2009-10-06 12:20:49 +0100" MODIFIED_BY="Lindsay Stead">
<UP_TO_DATE>
<DATE DAY="5" MONTH="10" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="5" MONTH="10" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="1997"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="1997"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2000"/>
</DATES>
<WHATS_NEW MODIFIED="2011-06-22 10:05:12 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-06-22 10:05:12 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="22" MONTH="6" YEAR="2011"/>
<DESCRIPTION>
<P>Additional table converted to appendix to correct pdf format</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2011-06-22 10:04:58 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2011-06-22 10:04:58 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="6" MONTH="10" YEAR="2009"/>
<DESCRIPTION>
<P>Searches updated; no new included studies. Effects expressed as risk ratios instead of odds ratios</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-10-06 12:20:57 +0100" MODIFIED_BY="Lindsay Stead">
<DATE DAY="8" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-05-08 14:34:17 +0100" MODIFIED_BY="L S">
<DATE DAY="26" MONTH="4" YEAR="2007"/>
<DESCRIPTION>
<P>Search updated, no new trials found</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-05-08 14:36:28 +0100" MODIFIED_BY="L S">
<DATE DAY="27" MONTH="8" YEAR="2003"/>
<DESCRIPTION>
<P>Search updated. One study (Hatsukami 2003) added to excluded studies list. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-05-08 14:47:20 +0100" MODIFIED_BY="L S">
<DATE DAY="15" MONTH="11" YEAR="2001"/>
<DESCRIPTION>
<P>Search updated, no new trials found</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2008-05-08 15:02:35 +0100" MODIFIED_BY="L S">
<DATE DAY="29" MONTH="8" YEAR="2000"/>
<DESCRIPTION>
<P>This review was first published as part of the review 'Anxiolytics and antidepressants for smoking cessation'. From Issue 4 2000 of the Cochrane Library the two classes of pharmacotherapies are reviewed separately</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Department of Primary Health Care, University of Oxford</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>National Institute on Drug Abuse (NIDA)</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>NHS Research and Development National Cancer Programme, England</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2011-06-22 09:54:12 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-05-08 15:05:12 +0100" MODIFIED_BY="L S">
<TITLE MODIFIED="2008-05-08 15:05:12 +0100" MODIFIED_BY="L S">Do pharmacotherapies which reduce anxiety help smokers to quit</TITLE>
<SUMMARY_BODY>
<P>Anxiety can contribute to increased smoking, and may be a smoking withdrawal symptom. Medications to reduce anxiety (anxiolytics) may theoretically help smokers trying to quit. There have not been many trials, and none of them showed strong evidence of an effect on quitting.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-10-05 17:14:50 +0100" MODIFIED_BY="Lindsay Stead">
<ABS_BACKGROUND>
<P>There are two reasons to believe anxiolytics might help in smoking cessation. Anxiety may be a symptom of nicotine withdrawal. Secondly, smoking could be due to an attempt to self-medicate an anxiety problem.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-10-05 17:14:50 +0100" MODIFIED_BY="Lindsay Stead">
<P>The aim of this review is to assess the effectiveness of anxiolytic pharmacotherapy in aiding long term smoking cessation. The drugs include buspirone; diazepam; doxepin; meprobamate; ondansetron; and the beta-blockers metoprolol, oxprenolol and propanolol.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-10-05 17:12:56 +0100" MODIFIED_BY="Lindsay Stead">
<P>We searched the Cochrane Tobacco Addiction Group specialised register (most recent search October 2009), which includes trials indexed in MEDLINE, EMBASE, SciSearch and PsycINFO, and conference abstracts.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>We considered randomized trials comparing anxiolytic drugs to placebo or an alternative therapeutic control for smoking cessation. We excluded trials with less than six months follow up.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-10-05 17:13:38 +0100" MODIFIED_BY="Lindsay Stead">
<P>We extracted data in duplicate on the type of study population, the nature of the drug therapy, the outcome measures, method of randomization, and completeness of follow up.</P>
<P>The main outcome measure was abstinence from smoking after at least six months follow up in patients smoking at baseline. We used the most rigorous definition of abstinence for each trial, and biochemically validated rates if available. Where appropriate, we performed meta-analysis of relative risks using a fixed effect model.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>There was one trial each of the anxiolytics diazepam, meprobamate, metoprolol and oxprenolol. There were two trials of the anxiolytic buspirone. None of the trials showed strong evidence of an effect for any of these drugs in helping smokers to quit. However, confidence intervals were wide, and an effect of anxiolytics cannot be ruled out on current evidence.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>There is no consistent evidence that anxiolytics aid smoking cessation, but the available evidence does not rule out a possible effect.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2011-06-22 09:54:12 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2009-10-06 14:11:50 +0100" MODIFIED_BY="Lindsay Stead">
<P>Whilst nicotine replacement has become the most widely used pharmacotherapy for smoking cessation (<LINK REF="REF-Stead-2008" TYPE="REFERENCE">Stead 2008</LINK>), some smokers prefer a treatment which does not use nicotine. A range of other classes of pharmacotherapy have been tested for possible effectiveness, with the nicotine receptor agonist varenicline (<LINK REF="REF-Cahill-2008" TYPE="REFERENCE">Cahill 2008</LINK>)and the antidepressants bupropion and nortriptyline (<LINK REF="REF-Hughes-2007a" TYPE="REFERENCE">Hughes 2007a</LINK>) identified as established therapies. Anxiolytics have also been proposed as treatments. Anxiety is a symptom of nicotine withdrawal (<LINK REF="REF-Hughes-2007b" TYPE="REFERENCE">Hughes 2007b</LINK>), and smoking may decrease anxiety (<LINK REF="REF-Morissette-2007" TYPE="REFERENCE">Morissette 2007</LINK>; <LINK REF="REF-Zvolensky-2005" TYPE="REFERENCE">Zvolensky 2005</LINK>). Anxiolytics may therefore aid cessation by abating a withdrawal symptom or by replacing the reinforcing effects of nicotine. Although clonidine is sometimes considered an anxiolytic, its efficacy for smoking cessation is covered in a separate Cochrane review (<LINK REF="REF-Gourlay-2004" TYPE="REFERENCE">Gourlay 2004</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="2">Short-term Trials</HEADING>
<P>The focus of this review and meta-analysis is on trials which provide evidence for an effect on long-term smoking cessation and these are described in the Results section. Short-term trials investigating anxiolytics have also been completed, and they are described below.</P>
<SUBSECTION>
<HEADING LEVEL="3">Buspirone</HEADING>
<P>Buspirone is a non-benzodiazepine anxiolytic with effects on serotonin neurotransmission. It is non-sedating and non-addicting. Doses used in smoking cessation trials have ranged from a maximum of 30 mg/day to 60 mg/day, over a period of nine to thirteen weeks, beginning therapy between two and three weeks before the quit date. Three short term studies have provided inconsistent evidence of an effect either on immediate abstinence rates or on withdrawal symptoms. <LINK REF="STD-West-1991" TYPE="STUDY">West 1991</LINK> (61 smokers) found an effect on abstinence at four weeks (47% versus 16%, P &lt; 0.025), but no differences on withdrawal symptom scores (including anxiety) amongst abstinent subjects. <LINK REF="STD-Robinson-1992" TYPE="STUDY">Robinson 1992</LINK> (54 smokers) failed to detect an effect of buspirone on any withdrawal symptoms or abstinence rates; two-week abstinence rates were 62% for buspirone and 52% for placebo. <LINK REF="STD-Hilleman-1992" TYPE="STUDY">Hilleman 1992</LINK> (37 smokers) found statistically significant (P &lt; 0.05) reductions in craving, anxiety, irritability, restlessness and sadness after seven days of attempted abstinence in the treated group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Diazepam</HEADING>
<P>This tranquilliser has been used in one long-term smoking cessation trial described in the Results section.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Meprobamate</HEADING>
<P>This tranquilliser has been used in one long-term smoking cessation trial described in the Results section.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Ondansetron</HEADING>
<P>Ondansetron is a serotonin 5-HT3 antagonist, which has been proposed for smoking therapy on the basis that 5-HT3 antagonists should reduce the reinforcing effect of nicotine. <LINK REF="STD-Zacny-1993" TYPE="STUDY">Zacny 1993</LINK> investigated the effect of ondansetron on tobacco consumption under laboratory conditions and found no evidence that it altered smoking behaviour. <LINK REF="STD-West-1996" TYPE="STUDY">West 1996</LINK> randomized 101 smokers to ondansetron 0.25 mg twice a day or to placebo for two weeks before and four weeks after a quit date. Subjects also received group-oriented behavioural therapy. At four-week follow up from the quit date, they found no significant difference in continuous abstinence rates, validated by salivary cotinine. Abstinence rates were 59% for ondansetron and 66% for placebo. Although the relatively high success rate from the group therapy could have masked any effect of the drug, it would be less likely to have affected withdrawal symptom severity, which did not differ between the groups. Neither group showed any marked increase in anxiety.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Beta-blockers</HEADING>
<P>Beta-blockers have potential anxiolytic effects, and for this reason have been tested for smoking withdrawal activity. <LINK REF="STD-Farebrother-1980" TYPE="STUDY">Farebrother 1980</LINK> (73 subjects) failed to find any effect of propanolol (40 mg three times a day) on abstinence at the end of eight weeks treatment, with a high drop out rate and low success rates in both treated (9%) and placebo (8%) groups.</P>
</SUBSECTION>
</SUBSECTION>
</BACKGROUND>
<OBJECTIVES>
<P>To assess the evidence for the effectiveness in assisting long-term smoking cessation drugs with anxiolytic properties including: buspirone, diazepam, meprobamate, metoprolol, ondansetron, oxprenolol, propanolol.</P>
<P>For each drug identified as having been used in a smoking cessation trial, the hypothesis tested was that it was more effective than placebo, or an alternative treatment, in achieving long-term smoking cessation.</P>
</OBJECTIVES>
<METHODS MODIFIED="2011-06-22 09:54:12 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2009-10-06 12:23:32 +0100" MODIFIED_BY="Lindsay Stead">
<CRIT_STUDIES>
<P>Randomized trials against placebo or an alternative therapeutic control.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Any smokers.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-10-06 12:23:32 +0100" MODIFIED_BY="Lindsay Stead">
<P>Treatment with any drug with anxiolytic properties, including beta blockers, but excluding clonidine which is covered by a separate review (<LINK REF="REF-Gourlay-2004" TYPE="REFERENCE">Gourlay 2004</LINK>).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>Abstinence from smoking, assessed at follow up at least six months from start of treatment.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-10-06 14:35:43 +0100" MODIFIED_BY="Lindsay Stead">
<P>Studies were identified from the Tobacco Addiction Group's specialised register. All trials using pharmacotherapy other than nicotine, bupropion, nortriptyline, varenicline, clonidine or lobeline for smoking cessation were found, and those using drugs generally classified as having an anxiolytic effect were selected for consideration for inclusion in this review. The citation lists of these studies, previous reviews of non-nicotine pharmacotherapy (<LINK REF="REF-Fagerstrom-2006" TYPE="REFERENCE">Fagerstrom 2006</LINK>; <LINK REF="REF-George-2004" TYPE="REFERENCE">George 2004</LINK>; <LINK REF="REF-McRobbie-2005" TYPE="REFERENCE">McRobbie 2005</LINK>; <LINK REF="REF-Siu-2007" TYPE="REFERENCE">Siu 2007</LINK>) and abstracts from the meetings of the Society for Research on Nicotine and Tobacco were checked. An additional search was made of MEDLINE (most recent search, via PubMed, October 5th 2009) and EMBASE (most recent search, via Ovid, 2009 week 40) using the search terms 'Anti-Anxiety Agents/exp' (MEDLINE) or 'Anxiolytic Agent /exp' (EMBASE) or any drug already identified as relevant from the register, combined with 'smok* or tobacco'.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2011-06-22 09:54:12 +0100" MODIFIED_BY="[Empty name]">
<P>Data on the number of study participants who had ceased to smoke at final follow up were extracted by LS and TL independently.</P>
<P>In each study the strictest available criteria to define cessation were used, so figures for sustained abstinence were extracted in preference to point prevalence where both were presented. In studies that used biochemical validation of cessation, only those subjects meeting the criteria for biochemically confirmed abstinence were regarded as having stopped smoking. Subjects in either group lost to follow up were regarded as being continuing smokers. As far as possible an Intention-to-treat analysis is applied. Where subjects appeared to have been randomized but were not included in the data presented by the author this is noted in the study description (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table).</P>
<P>Data on the number of quitters in the treatment and control groups, and a risk ratio with confidence intervals, is presented in the Summary of Analyses. For each type of drug where more than one eligible trial was identified, an estimate of the most likely effect size is calculated using the Mantel-Haenszel fixed-effect method, in line with the current recommendation of the <LINK REF="REF-Cochrane-Handbook" TYPE="REFERENCE">Cochrane Handbook</LINK>. Although a summary statistic is displayed, the conclusions which can be drawn from it must be cautious. Where trials are small and few in number the confidence intervals will be wide.</P>
<P>Unpublished studies or studies found only as abstracts were included where sufficient detail was available. Authors were contacted for further data if necessary.</P>
<P>We include in this updated review the Tobacco Addiction Group glossary of tobacco-specific terms (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>).</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2009-10-21 11:36:52 +0100" MODIFIED_BY="Lindsay Stead">
<STUDY_DESCRIPTION MODIFIED="2009-10-06 13:36:32 +0100" MODIFIED_BY="Lindsay Stead">
<P>Additonal details of included and studies are given in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table. Studies that appeared relevant but were not included are listed in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table.</P>
<SUBSECTION>
<HEADING LEVEL="3">Buspirone</HEADING>
<P>Three trials with long-term follow up were identified. Cinciripini 1995 and <LINK REF="STD-Schneider-1996" TYPE="STUDY">Schneider 1996</LINK> compared buspirone to placebo. Cinciripini divided subjects into low and high anxiety groups on the basis of a Profile of Mood States Anxiety/Tension Scale (POMS) before randomization. Because there was evidence for a therapy/anxiety state interaction the two groups were entered separately into the meta-analysis (<LINK REF="STD-Cinciripini-1995--L" TYPE="STUDY">Cinciripini 1995 L</LINK>; <LINK REF="STD-Cinciripini-1995-H" TYPE="STUDY">Cinciripini 1995 H</LINK>). <LINK REF="STD-Hilleman-1994" TYPE="STUDY">Hilleman 1994</LINK> compared buspirone with fixed-dose or tapered dose transdermal nicotine, and since this study lacks a placebo group it is not compared directly with the other two trials. Two studies compared a combination of sertraline (an antidepressant) and buspirone to placebo. We excluded these because the effect of buspirone could not be evaluated separately</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Diazepam</HEADING>
<P>
<LINK REF="STD-Hao-1988" TYPE="STUDY">Hao 1988</LINK> in China tested the benzodiazepine, diazepam in a randomized design against both placebo and clonidine. Suggested dosage was 7.5 - 15 mg per day for four weeks. Subjects also had three individual sessions with a psychiatrist. Long-term follow up was stated to be at an average of 4.5 months from the end of drug therapy, which has been treated as six months from the quit date, sufficiently long to meet the inclusion criteria.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Meprobamate</HEADING>
<P>
<LINK REF="STD-Schwartz-1968" TYPE="STUDY">Schwartz 1968</LINK> tested meprobamate (400 mg per day) in a factorial design trial which randomized subjects to prescription or placebo, alone or in combination with group or individual counselling. Although one-year and eighteen-month follow-up results are reported, absolute abstinence at any point is not used an outcome measure, with success being classified as a reduction of 85% or more in baseline smoking. Subjects could be counted as successes at any follow-up point, irrespective of their smoking status at previous points.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Ondansetron</HEADING>
<P>No trials met the inclusion criteria.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Beta-blockers</HEADING>
<P>
<LINK REF="STD-Dow-1984" TYPE="STUDY">Dow 1984</LINK> tested two types; metoprolol (100 mg twice a day) or oxprenolol (80 mg twice a day) against placebo, using a double dummy technique, with follow up at 12 months.</P>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>Very few of the trials reported randomization methods in sufficient detail for the possibility of allocation bias to be discounted. The definition of abstinence was not always explicit and biochemical validation of self-reported smoking status was not always used.</P>
<P>Descriptions of trial design are given in the table 'Characteristics of Included Studies'.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2009-10-21 11:36:52 +0100" MODIFIED_BY="Lindsay Stead">
<SUBSECTION>
<HEADING LEVEL="3">Buspirone</HEADING>
<P>In the two trials comparing buspirone with placebo, the pooled risk ratio (RR) was 0.76; 95% confidence interval (CI) 0.42 to 1.37; <I>Analysis 1.1.1</I>). The point estimate does not suggest effectiveness but the confidence intervals do not rule out a clinically useful effect. The trial comparing buspirone with a known effective treatment, transdermal nicotine (<LINK REF="STD-Hilleman-1994" TYPE="STUDY">Hilleman 1994</LINK>), failed to detect evidence of a difference between the nicotine patch and buspirone therapies (RR 1.08; 95% CI 0.70 to 1.65; <I>Analysis 1.1.2</I>). Cinciripini found a significant benefit of buspirone among the high anxiety subjects at the end of drug therapy (88% versus 61%, P &lt; 0.01). However, <LINK REF="STD-Schneider-1996" TYPE="STUDY">Schneider 1996</LINK> did not replicate this effect.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Diazepam</HEADING>
<P>One trial (<LINK REF="STD-Hao-1988" TYPE="STUDY">Hao 1988</LINK>) found no difference between diazepam and placebo at long-term follow up, (RR 1.00, 95% CI 0.56 to 1.80; <I>Analysis 2.1</I>); both groups had behavioural therapy and quit rates were relatively high, 37% in each. Withdrawal symptom scores were also similar in each group. However the questionnaire contained 10 items so any effect on anxiety may have been obscured.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Meprobamate</HEADING>
<P>One trial (<LINK REF="STD-Schwartz-1968" TYPE="STUDY">Schwartz 1968</LINK>; <I>Analysis 3</I>) found no evidence for a beneficial effect of this tranquilliser on reduction in smoking. Subjects on placebo did consistently better than those on meprobamate within each counselling condition. The authors suggest that side effects of the drug such as drowsiness and sensitivity to alcohol 'may have been detrimental to the subject's own determination to stop smoking'.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Ondansetron</HEADING>
<P>There was no evidence from long-term trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Beta-blockers</HEADING>
<P>One trial (<LINK REF="STD-Dow-1984" TYPE="STUDY">Dow 1984</LINK>) found a cessation rate at 12-month follow up of 17% for oxprenolol, 24% for metoprolol and 3% for placebo. The difference was statistically significant for metoprolol (<I>Analysis 4.1.2</I>) but not for oxprenolol (<I>Analysis 4.1.1</I>). However the marked difference between the groups on active drug and placebo developed after the end of drug treatment, which is surprising.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2009-10-06 18:02:57 +0100" MODIFIED_BY="Lindsay Stead">
<P>Trial data on anxiolytics for smoking cessation are limited. Although there are no strongly positive long-term studies, the confidence intervals for the available data do not rule out a possible effect. The rationale for studying anxiolytics is based on two assumptions: a) cessation causes increased anxiety (<LINK REF="REF-Hughes-2007b" TYPE="REFERENCE">Hughes 2007b</LINK>), and b) smoking relieves this (<LINK REF="REF-Morissette-2007" TYPE="REFERENCE">Morissette 2007</LINK>; <LINK REF="REF-Zvolensky-2005" TYPE="REFERENCE">Zvolensky 2005</LINK>). Some studies cast doubt on these assumptions (<LINK REF="REF-West-1997" TYPE="REFERENCE">West 1997</LINK>; <LINK REF="REF-Parrott-1999" TYPE="REFERENCE">Parrott 1999</LINK>). On the other hand, people who are still smoking may be those with minor or major psychiatric comorbidity (<LINK REF="REF-Morissette-2007" TYPE="REFERENCE">Morissette 2007</LINK>; <LINK REF="REF-Zvolensky-2005" TYPE="REFERENCE">Zvolensky 2005</LINK>); thus, using anxiolytics for highly anxious patients may prove helpful. In one study high anxiety patients appeared to benefit more (<LINK REF="STD-Cinciripini-1995-H" TYPE="STUDY">Cinciripini 1995 H</LINK>) whilst in the other they did not (<LINK REF="STD-Schneider-1996" TYPE="STUDY">Schneider 1996</LINK>). Two trials combining buspirone with the selective serotonin reuptake inhibitor (SSRI) sertraline as an adjunct to cognitive behavioural therapy have both reported significant long tem effects (<LINK REF="STD-Carr_x00e3_o-2007" TYPE="STUDY">Carrão 2007</LINK>, <LINK REF="STD-Ionescu-2008" TYPE="STUDY">Ionescu 2008</LINK>). These are excluded from the review because it is not possible to separate out the effect of the anxiolytic buspirone alone, from that of the SSRI. SSRIs alone do not appear to aid long term cessation (<LINK REF="REF-Hughes-2007a" TYPE="REFERENCE">Hughes 2007a</LINK>). However, the authors of the above two trials hypothesize a mechanism in which the combined use of these would be effective. Many of the anxiolytics have significant side effects such as a risk of abuse or dependence, and sedation. Given the reluctance of smokers to take medication for cessation, probably only anxiolytics with benign side-effect profiles (e.g. buspirone) would be acceptable to smokers.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>The available evidence neither supports nor rules out an effect of anxiolytics on smoking cessation. In view of this uncertainty and the side effects of the drugs, there is little justification for using them. One drug with some anxiolytic effects, clonidine, does show evidence of efficacy (<LINK REF="REF-Gourlay-2004" TYPE="REFERENCE">Gourlay 2004</LINK>), but the incidence of side effects from clonidine is relatively high.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Further studies of anxiolytics for highly anxious smokers may be reasonable.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>JR Hughes is supported by Research Scientist Development Award DA-00490 from the National Institute on Drug Abuse.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>JR Hughes has received consultancy fees from pharmaceutical companies.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Authors jointly conceived and prepared review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES>
<P>This review was first published as part of the review 'Anxiolytics and antidepressants for smoking cessation'. From Issue 4 2000 of the Cochrane Library the two classes of drugs are reviewed separately.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2009-10-06 14:36:30 +0100" MODIFIED_BY="Lindsay Stead">
<STUDIES MODIFIED="2009-10-06 14:36:30 +0100" MODIFIED_BY="Lindsay Stead">
<INCLUDED_STUDIES MODIFIED="2009-10-06 13:39:49 +0100" MODIFIED_BY="Lindsay Stead">
<STUDY DATA_SOURCE="PUB" ID="STD-Cinciripini-1995--L" MODIFIED="2008-05-08 15:25:54 +0100" MODIFIED_BY="L S" NAME="Cinciripini 1995  L" YEAR="1995">
<REFERENCE MODIFIED="2008-05-08 15:25:54 +0100" MODIFIED_BY="L S" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cinciripini PM, Lapitsky LG, Seay S, Wallfisch A, Meyer WJ, Vanvunakis H</AU>
<TI>A placebo-controlled evaluation of the effects of buspirone on smoking cessation - differences between high-anxiety and low-anxiety smokers [published erratum appears in J Clin Psychopharmacol 1995;15:408]</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1995</YR>
<VL>15</VL>
<PG>182-91</PG>
<IDENTIFIERS MODIFIED="2008-05-08 15:25:54 +0100" MODIFIED_BY="L S"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cinciripini-1995-H" MODIFIED="2008-05-08 15:26:07 +0100" MODIFIED_BY="L S" NAME="Cinciripini 1995 H" YEAR="1995">
<REFERENCE MODIFIED="2008-05-08 15:26:07 +0100" MODIFIED_BY="L S" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cinciripini PM, Lapitsky LG, Seay S, Wallfisch A, Meyer WJ, Vanvunakis H</AU>
<TI>A placebo-controlled evaluation of the effects of buspirone on smoking cessation - differences between high-anxiety and low-anxiety smokers [published erratum appears in J Clin Psychopharmacol 1995;15:408]</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1995</YR>
<VL>15</VL>
<PG>182-91</PG>
<IDENTIFIERS MODIFIED="2008-05-08 15:26:07 +0100" MODIFIED_BY="L S"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dow-1984" MODIFIED="2008-05-08 15:26:14 +0100" MODIFIED_BY="L S" NAME="Dow 1984" YEAR="1984">
<REFERENCE MODIFIED="2008-05-08 15:26:14 +0100" MODIFIED_BY="L S" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dow RJ, Fee WM</AU>
<TI>Use of beta-blocking agents with group therapy in a smoking withdrawal clinic</TI>
<SO>Journal of the Royal Society of Medicine</SO>
<YR>1984</YR>
<VL>77</VL>
<PG>648-51</PG>
<IDENTIFIERS MODIFIED="2008-05-08 15:26:14 +0100" MODIFIED_BY="L S"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hao-1988" MODIFIED="2008-05-08 15:26:22 +0100" MODIFIED_BY="L S" NAME="Hao 1988" YEAR="">
<REFERENCE MODIFIED="2008-05-08 15:26:22 +0100" MODIFIED_BY="L S" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hao W, Young D, Wei H [corrected to Hao-W]</AU>
<TI>Effect of clonidine on cigarette cessation and in the alleviation of withdrawal symptoms [published erratum appears in Br J Addict 1988;83:1467]</TI>
<SO>British Journal of Addiction</SO>
<YR>1988</YR>
<VL>83</VL>
<PG>1221-6</PG>
<IDENTIFIERS MODIFIED="2008-05-08 15:26:22 +0100" MODIFIED_BY="L S"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hilleman-1994" MODIFIED="2008-05-08 15:26:30 +0100" MODIFIED_BY="L S" NAME="Hilleman 1994" YEAR="1994">
<REFERENCE MODIFIED="2008-05-08 15:26:30 +0100" MODIFIED_BY="L S" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hilleman DE, Mohiuddin SM, Delcore MG</AU>
<TI>Comparison of fixed-dose transdermal nicotine, tapered-dose transdermal nicotine, and buspirone in smoking cessation</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>1994</YR>
<VL>34</VL>
<PG>222-4</PG>
<IDENTIFIERS MODIFIED="2008-05-08 15:26:30 +0100" MODIFIED_BY="L S"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schneider-1996" MODIFIED="2008-05-08 15:26:37 +0100" MODIFIED_BY="L S" NAME="Schneider 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-05-08 15:26:37 +0100" MODIFIED_BY="L S" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schneider NG, Olmstead RE, Steinberg C, Sloan K, Daims RM, Brown HV</AU>
<TI>Efficacy of buspirone in smoking cessation - a placebo-controlled trial</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>1996</YR>
<VL>60</VL>
<PG>568-75</PG>
<IDENTIFIERS MODIFIED="2008-05-08 15:26:37 +0100" MODIFIED_BY="L S"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schwartz-1968" MODIFIED="2008-05-08 15:26:55 +0100" MODIFIED_BY="L S" NAME="Schwartz 1968" YEAR="1968">
<REFERENCE MODIFIED="2008-05-08 15:26:48 +0100" MODIFIED_BY="L S" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schwartz JL, Dubitzky M</AU>
<TI>One-year follow-up results of a smoking cessation program</TI>
<SO>Canadian Journal of Public Health</SO>
<YR>1968</YR>
<VL>59</VL>
<PG>161-5</PG>
<IDENTIFIERS MODIFIED="2008-05-08 15:26:48 +0100" MODIFIED_BY="L S"/>
</REFERENCE>
<REFERENCE MODIFIED="2008-05-08 15:26:55 +0100" MODIFIED_BY="L S" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schwartz JL, Dubitzky M</AU>
<TI>The smoking control research project: purpose, design, and initial results</TI>
<SO>Psychological Reports</SO>
<YR>1967</YR>
<VL>20</VL>
<PG>367-76</PG>
<IDENTIFIERS MODIFIED="2008-05-08 15:26:55 +0100" MODIFIED_BY="L S"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2009-10-06 14:36:30 +0100" MODIFIED_BY="Lindsay Stead">
<STUDY DATA_SOURCE="PUB" ID="STD-Bartlett-1957" NAME="Bartlett 1957" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bartlett WA, Whitehead RW</AU>
<TI>The effectiveness of meprobamate and lobeline as smoking deterrents</TI>
<SO>Journal of Laboratory and Clinical Medicine</SO>
<YR>1957</YR>
<VL>50</VL>
<NO>2</NO>
<PG>278-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carr_x00e3_o-2007" MODIFIED="2009-10-06 14:26:46 +0100" MODIFIED_BY="Lindsay Stead" NAME="Carrão 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-10-06 14:26:46 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carrão JL, Moreira LB, Fuchs FD</AU>
<TI>The efficacy of the combination of sertraline with buspirone for smoking cessation. A randomized clinical trial in nondepressed smokers</TI>
<SO>European Archives of Psychiatry &amp; Clinical Neuroscience</SO>
<YR>2007</YR>
<VL>257</VL>
<PG>383-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Farebrother-1980" MODIFIED="2008-05-08 15:27:10 +0100" MODIFIED_BY="L S" NAME="Farebrother 1980" YEAR="1980">
<REFERENCE MODIFIED="2008-05-08 15:27:10 +0100" MODIFIED_BY="L S" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Farebrother MJ, Pearce SJ, Turner P, Appleton DR</AU>
<TI>Propranolol and giving up smoking</TI>
<SO>British Journal of Diseases of the Chest</SO>
<YR>1980</YR>
<VL>74</VL>
<PG>95-6</PG>
<IDENTIFIERS MODIFIED="2008-05-08 15:27:10 +0100" MODIFIED_BY="L S"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gawin-1989" MODIFIED="2008-05-08 15:27:20 +0100" MODIFIED_BY="L S" NAME="Gawin 1989" YEAR="1989">
<REFERENCE MODIFIED="2008-05-08 15:27:20 +0100" MODIFIED_BY="L S" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gawin F, Compton M, Byck R</AU>
<TI>Buspirone reduces smoking [letter]</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1989</YR>
<VL>46</VL>
<NO>3</NO>
<PG>288-9</PG>
<IDENTIFIERS MODIFIED="2008-05-08 15:27:20 +0100" MODIFIED_BY="L S"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hatsukami-2003" MODIFIED="2008-05-08 15:28:02 +0100" MODIFIED_BY="L S" NAME="Hatsukami 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-05-08 15:28:02 +0100" MODIFIED_BY="L S" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hatsukami DK, Jensen J, Brauer LH, Mooney M, Schulte S, Sofuoglu M et al</AU>
<TI>Lack of effect of 5HT(3) antagonist in mediating subjective and behavioral responses to cotinine</TI>
<SO>Pharmacology Biochemistry and Behavior</SO>
<YR>2003</YR>
<VL>75</VL>
<PG>1-7</PG>
<IDENTIFIERS MODIFIED="2008-05-08 15:28:02 +0100" MODIFIED_BY="L S"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hilleman-1992" MODIFIED="2008-05-08 15:28:12 +0100" MODIFIED_BY="L S" NAME="Hilleman 1992" YEAR="1992">
<REFERENCE MODIFIED="2008-05-08 15:28:12 +0100" MODIFIED_BY="L S" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hilleman DE, Mohiuddin SM, del Core MG, Sketch MH</AU>
<TI>Effect of buspirone on withdrawal symptoms associated with smoking cessation</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1992</YR>
<VL>152</VL>
<PG>350-2</PG>
<IDENTIFIERS MODIFIED="2008-05-08 15:28:12 +0100" MODIFIED_BY="L S"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Ionescu-2008" MODIFIED="2009-10-06 14:36:30 +0100" MODIFIED_BY="Lindsay Stead" NAME="Ionescu 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-10-06 14:36:30 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Daniela Ionescu, Carmen Cristescu</AU>
<TI>The combination of sertraline with buspirone for smoking cessation process - the effectiveness and adverse events</TI>
<SO>Toxicology Letters</SO>
<YR>2008</YR>
<VL>180</VL>
<NO>Suppl 1</NO>
<PG>S130</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1016/j.toxlet.2008.06.751"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Robinson-1991" MODIFIED="2008-05-08 15:28:23 +0100" MODIFIED_BY="L S" NAME="Robinson 1991" YEAR="1991">
<REFERENCE MODIFIED="2008-05-08 15:28:23 +0100" MODIFIED_BY="L S" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Robinson MD, Smith WA, Cederstrom EA, Sutherland DE</AU>
<TI>Buspirone effect on tobacco withdrawal symptoms: a pilot study</TI>
<SO>Journal of the American Board of Family Practice</SO>
<YR>1991</YR>
<VL>4</VL>
<NO>2</NO>
<PG>89-94</PG>
<IDENTIFIERS MODIFIED="2008-05-08 15:28:23 +0100" MODIFIED_BY="L S"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Robinson-1992" MODIFIED="2008-05-08 15:28:17 +0100" MODIFIED_BY="L S" NAME="Robinson 1992" YEAR="1992">
<REFERENCE MODIFIED="2008-05-08 15:28:17 +0100" MODIFIED_BY="L S" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Robinson MD, Pettice YL, Smith WA, Cederstrom EA, Sutherland DE, Davis H</AU>
<TI>Buspirone effect on tobacco withdrawal symptoms: a randomized placebo-controlled trial</TI>
<SO>Journal of the American Board of Family Practice</SO>
<YR>1992</YR>
<VL>5</VL>
<NO>1</NO>
<PG>1-9</PG>
<IDENTIFIERS MODIFIED="2008-05-08 15:28:17 +0100" MODIFIED_BY="L S"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-West-1991" MODIFIED="2008-05-08 15:28:31 +0100" MODIFIED_BY="L S" NAME="West 1991" YEAR="1991">
<REFERENCE MODIFIED="2008-05-08 15:28:31 +0100" MODIFIED_BY="L S" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>West R, Hajek P, McNeill A</AU>
<TI>Effect of buspirone on cigarette withdrawal symptoms and short-term abstinence rates in a smokers clinic</TI>
<SO>Psychopharmacology Berlin</SO>
<YR>1991</YR>
<VL>104</VL>
<PG>91-6</PG>
<IDENTIFIERS MODIFIED="2008-05-08 15:28:31 +0100" MODIFIED_BY="L S"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-West-1996" MODIFIED="2008-05-08 15:28:42 +0100" MODIFIED_BY="L S" NAME="West 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-05-08 15:28:42 +0100" MODIFIED_BY="L S" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>West R, Hajek P</AU>
<TI>Randomized controlled trial of ondansetron in smoking cessation</TI>
<SO>Psychopharmacology Berlin</SO>
<YR>1996</YR>
<VL>126</VL>
<PG>95-6</PG>
<IDENTIFIERS MODIFIED="2008-05-08 15:28:42 +0100" MODIFIED_BY="L S"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zacny-1993" MODIFIED="2008-05-08 15:28:49 +0100" MODIFIED_BY="L S" NAME="Zacny 1993" YEAR="1993">
<REFERENCE MODIFIED="2008-05-08 15:28:49 +0100" MODIFIED_BY="L S" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zacny JP, Apfelbaum JL, Lichtor JL, Zaragoza JG</AU>
<TI>Effects of 5-hydroxytryptamine3 antagonist, ondansetron, on cigarette smoking, smoke exposure and mood in humans</TI>
<SO>Pharmacology, Biochemistry, and Behavior</SO>
<YR>1992</YR>
<VL>44</VL>
<PG>387-91</PG>
<IDENTIFIERS MODIFIED="2008-05-08 15:28:49 +0100" MODIFIED_BY="L S"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2009-10-06 14:35:02 +0100" MODIFIED_BY="Lindsay Stead">
<ADDITIONAL_REFERENCES MODIFIED="2009-10-06 14:31:03 +0100" MODIFIED_BY="Lindsay Stead">
<REFERENCE ID="REF-Cahill-2008" MODIFIED="2009-10-06 12:27:36 +0100" MODIFIED_BY="Lindsay Stead" NAME="Cahill 2008" TYPE="COCHRANE_REVIEW">
<AU>Cahill K, Stead LF, Lancaster T</AU>
<TI>Nicotine receptor partial agonists for smoking cessation</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2009-10-06 12:27:36 +0100" MODIFIED_BY="Lindsay Stead">
<IDENTIFIER MODIFIED="2009-10-06 12:27:36 +0100" MODIFIED_BY="Lindsay Stead" TYPE="DOI" VALUE="10.1002/14651858.CD006103.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cochrane-Handbook" NAME="Cochrane Handbook" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]</TI>
<SO>http://www.cochrane.org/resources/handbook/hbook.htm (accessed 18th April 2007)</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fagerstrom-2006" NAME="Fagerstrom 2006" TYPE="JOURNAL_ARTICLE">
<AU>Fagerstrom K, Balfour DJK</AU>
<TI>Neuropharmacology and potential efficacy of new treatments for tobacco dependence</TI>
<SO>Expert Opinion on Investigational Drugs</SO>
<YR>2006</YR>
<VL>15</VL>
<NO>2</NO>
<PG>107-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-George-2004" NAME="George 2004" TYPE="JOURNAL_ARTICLE">
<AU>George TP, O'Malley SS</AU>
<TI>Current pharmacological treatments for nicotine dependence</TI>
<SO>Trends in Pharmacological Sciences</SO>
<YR>2004</YR>
<VL>25</VL>
<NO>1</NO>
<PG>42-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gourlay-2004" MODIFIED="2008-05-08 15:23:01 +0100" MODIFIED_BY="L S" NAME="Gourlay 2004" TYPE="COCHRANE_REVIEW">
<AU>Gourlay SG, Stead LF, Benowitz NL</AU>
<TI>Clonidine for smoking cessation</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2008-05-08 15:23:01 +0100" MODIFIED_BY="L S">
<IDENTIFIER MODIFIED="2008-05-08 15:23:00 +0100" MODIFIED_BY="L S" TYPE="DOI" VALUE="10.1002/14651858.CD000058.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hughes-2007a" MODIFIED="2009-10-06 12:45:35 +0100" MODIFIED_BY="Lindsay Stead" NAME="Hughes 2007a" TYPE="COCHRANE_REVIEW">
<AU>Hughes JR, Stead LF, Lancaster T</AU>
<TI>Antidepressants for smoking cessation</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2009-10-06 12:45:35 +0100" MODIFIED_BY="Lindsay Stead">
<IDENTIFIER MODIFIED="2009-10-06 12:45:35 +0100" MODIFIED_BY="Lindsay Stead" TYPE="DOI" VALUE="10.1002/14651858.CD000031.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hughes-2007b" MODIFIED="2009-10-06 14:11:50 +0100" MODIFIED_BY="Lindsay Stead" NAME="Hughes 2007b" TYPE="JOURNAL_ARTICLE">
<AU>Hughes JR</AU>
<TI>Effects of abstinence from tobacco: valid symptoms and time course</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2007</YR>
<VL>9</VL>
<NO>3</NO>
<PG>315-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McRobbie-2005" NAME="McRobbie 2005" TYPE="JOURNAL_ARTICLE">
<AU>McRobbie H, Lee M, Juniper Z</AU>
<TI>Non-nicotine pharmacotherapies for smoking cessation</TI>
<SO>Respiratory Medicine</SO>
<YR>2005</YR>
<VL>99</VL>
<PG>1203-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Morissette-2007" NAME="Morissette 2007" TYPE="JOURNAL_ARTICLE">
<AU>Morisette SB, Tull MT, Gulliver SB, Kamholz BW, Zimering RT</AU>
<TI>Anxiety, anxiety disorders, tobacco use, and nicotine: a critical review of interrelationships</TI>
<SO>Psychological Bulletin</SO>
<YR>2007</YR>
<VL>133</VL>
<NO>2</NO>
<PG>245-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Parrott-1999" NAME="Parrott 1999" TYPE="JOURNAL_ARTICLE">
<AU>Parrott AC</AU>
<TI>Does cigarette smoking cause stress?</TI>
<SO>The American Psychologist</SO>
<YR>1999</YR>
<VL>54</VL>
<PG>817-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Siu-2007" NAME="Siu 2007" TYPE="JOURNAL_ARTICLE">
<AU>Siu ECK, Tyndale RF</AU>
<TI>Non-nicotinic therapies for smoking cessation</TI>
<SO>Annual Review of Pharmacology and Toxicology</SO>
<YR>2007</YR>
<VL>47</VL>
<PG>541-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stead-2008" MODIFIED="2009-10-06 12:42:26 +0100" MODIFIED_BY="Lindsay Stead" NAME="Stead 2008" TYPE="COCHRANE_REVIEW">
<AU>Stead LF, Perera R, Bullen C, Mant D, Lancaster T</AU>
<TI>Nicotine replacement therapy for smoking cessation</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2009-10-06 12:42:26 +0100" MODIFIED_BY="Lindsay Stead">
<IDENTIFIER MODIFIED="2009-10-06 12:42:26 +0100" MODIFIED_BY="Lindsay Stead" TYPE="DOI" VALUE="10.1002/14651858.CD000146.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-West-1997" NAME="West 1997" TYPE="JOURNAL_ARTICLE">
<AU>West R, Hajek P</AU>
<TI>What happens to anxiety levels on giving up smoking?</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1997</YR>
<VL>154</VL>
<PG>1589-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zvolensky-2005" MODIFIED="2008-05-08 15:32:16 +0100" MODIFIED_BY="L S" NAME="Zvolensky 2005" TYPE="JOURNAL_ARTICLE">
<AU>Zvolensky MJ, Feldner MT, Leen-Feldner EW, McLeish AC</AU>
<TI>Smoking and panic attacks, panic disorder, and agoraphobia: a review of the empirical literature</TI>
<SO>Clinical Psychology Review</SO>
<YR>2005</YR>
<VL>6</VL>
<PG>761-89</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2009-10-06 14:35:02 +0100" MODIFIED_BY="Lindsay Stead">
<REFERENCE ID="REF-Hughes-1997" MODIFIED="2008-05-08 15:33:05 +0100" MODIFIED_BY="L S" NAME="Hughes 1997" TYPE="COCHRANE_REVIEW">
<AU>Hughes JR, Stead LF, Lancaster T</AU>
<TI>Anxiolytics and antidepressants for smoking cessation</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1997</YR>
<NO>3</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hughes-2000" MODIFIED="2009-10-06 14:35:02 +0100" MODIFIED_BY="Lindsay Stead" NAME="Hughes 2000" TYPE="COCHRANE_REVIEW">
<AU>Hughes JR, Stead LF, Lancaster T</AU>
<TI>Anxiolytics for smoking cessation</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2009-10-06 14:35:02 +0100" MODIFIED_BY="Lindsay Stead">
<IDENTIFIER MODIFIED="2009-10-06 14:35:02 +0100" MODIFIED_BY="Lindsay Stead" TYPE="DOI" VALUE="10.1002/14651858.CD002849"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-10-21 11:42:14 +0100" MODIFIED_BY="Lindsay Stead">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-10-21 11:42:14 +0100" MODIFIED_BY="Lindsay Stead" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2009-10-21 11:42:14 +0100" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Cinciripini-1995--L">
<CHAR_METHODS MODIFIED="2009-10-06 14:37:28 +0100" MODIFIED_BY="Lindsay Stead">
<P>BUSPIRONE<BR/>Country: USA<BR/>Recruitment: volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-21 11:42:14 +0100" MODIFIED_BY="Lindsay Stead">
<P>101 subjects with &gt; 3 yr history of &gt;=15 cigs/day, divided into 'high anxiety' and 'low anxiety' groups on the basis of POMS anxiety score above or below 44. (48 smokers in low anxiety group)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Buspirone, for 12 wks, max 45mg/day for 4 wks pre quit date, increasing to max 60mg/day after quit.<BR/>2. Placebo<BR/>Both groups received 9 sessions of a cognitive behavioural intervention, and were required to pay a deposit of US$140 dollars, repayable in stages.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Cessation validated by salivary cotinine &lt;14 ng/ml at 12ms after end of group therapy. Slips were allowed if smoking occurred on less than 5 days since previous assessment.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>High anxiety and low anxiety groups entered separately, since there was evidence of interaction.<BR/>Numbers worked back from percentages and rounded up.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Cinciripini-1995-H">
<CHAR_METHODS>
<P>BUSPIRONE<BR/>See Cinciripini 1995 L - trial stratified by anxiety levels</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>53 smokers in high anxiety group</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>see above</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>see above</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>High anxiety and low anxiety groups entered separately, since there was evidence of interaction.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-10-06 14:39:43 +0100" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Dow-1984">
<CHAR_METHODS MODIFIED="2009-10-06 14:39:43 +0100" MODIFIED_BY="Lindsay Stead">
<P>BETA-BLOCKERS<BR/>Country: Scotland<BR/>Recruitment: Smoking withdrawal clinic waiting list<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>101/277 subjects found to be suitable for beta-blocker therapy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Oxprenolol 160 mg/day for 40 days<BR/>2. Metoprolol 200 mg/day for 40 days<BR/>3. Double dummy placebo<BR/>All received a standard course of group therapy and health education</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Cessation (not defined) at 12ms<BR/>No validation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-10-21 11:41:15 +0100" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Hao-1988">
<CHAR_METHODS MODIFIED="2009-10-06 14:40:43 +0100" MODIFIED_BY="Lindsay Stead">
<P>DIAZEPAM<BR/>Country: China<BR/>Recruitment: no details<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-21 11:41:15 +0100" MODIFIED_BY="Lindsay Stead">
<P>118 smokers, (111 males, 7 females) &gt;20cigs/day</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Diazepam ('Valium') recommended dosage 7.5mg/day for 4 wks<BR/>2. Clonidine, recommended dosage 0.225 mg/day for 4 wks<BR/>3. Matched placebo<BR/>All participants had 3 individual sessions with a psychiatrist</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Continuous abstinence at follow up on average 4.5ms from end of treatment. No biochemical validation, but confirmation sought from family and co-workers.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-05-08 15:33:39 +0100" MODIFIED_BY="L S">
<P>Efficacy of clonidine has been assessed in a separate Cochrane review (Gourlay 2004)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-10-06 14:40:56 +0100" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Hilleman-1994">
<CHAR_METHODS MODIFIED="2009-10-06 14:40:56 +0100" MODIFIED_BY="Lindsay Stead">
<P>BUSPIRONE<BR/>Country: USA<BR/>Recruitment: advertisement</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>208 smokers, &gt;1 pack/day, with more than one serious attempt to stop smoking, no history of psychiatric disorder</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Buspirone 15mg for 7 days then 30mg for 21 days<BR/>2. Fixed dose transdermal nicotine 21 or 22mg patch<BR/>3. Tapered dose 21 or 22mg, 14mg, 7mg patch<BR/>Behavioural support consisted of 12 weekly sessions</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 24 wks (criteria not specified), partial validation by random plasma thiocyanate testing.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Buspirone group compared with 2 and 3 combined</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-10-06 14:41:11 +0100" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Schneider-1996">
<CHAR_METHODS MODIFIED="2009-10-06 14:41:11 +0100" MODIFIED_BY="Lindsay Stead">
<P>BUSPIRONE<BR/>Country: USA<BR/>Recruitment: advertisements<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>100 subjects, &gt;10 cigs/day for &gt;5 years, previous attempt at quitting. No history of diagnosed anxiety or depression.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Buspirone max 30mg/day for 3 wks pre quit date, max 60mg/day for further 6 wks<BR/>2. Matched placebo<BR/>Both groups received controlled presentation (by video) of coping and relapse prevention skills. A total of 17 visits</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1 yr abstinence, with no reported slips, validated by CO =&lt; 8ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>24/124 smokers dropped out pre quit day, not included in analysis<BR/>Post hoc division into high and low anxiety groups. No evidence of differential effect.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-10-06 14:41:30 +0100" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Schwartz-1968">
<CHAR_METHODS MODIFIED="2009-10-06 14:41:30 +0100" MODIFIED_BY="Lindsay Stead">
<P>MEPROBAMATE<BR/>Country; USA<BR/>Recruitment: Volunteers in a health care plan<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>324 smokers, &gt;10cigs/day</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Tranquillizer alone<BR/>2. Placebo<BR/>3. Tranquilizer + individual counselling<BR/>4. Placebo + individual counselling<BR/>5. Tranquilizer + group counselling<BR/>6. Placebo + group counselling<BR/>7. Group counselling, no pill<BR/>8. Control I - no intervention<BR/>9. Control II - Completed psychosocial questionnaires and medical screening but no further intervention</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Success was defined by a reduction of &gt;85% from baseline smoking at follow up. Follow up at end of treatment (8 wks), 4ms and 1 yr, with telephone follow up of successes at 18ms</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>One year success rates used. 1 compared with 2, 3 with 4, and 5 with 6 as separate subgroups.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2009-10-06 13:42:24 +0100" MODIFIED_BY="Lindsay Stead" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Bartlett-1957">
<CHAR_REASON_FOR_EXCLUSION>
<P>Meprobamate - Two trials: 1st a cross-over trial comparing it with lobeline and placebo. 2nd comparing meprobamate and placebo, to be taken when withdrawal symptoms were felt by subjects. There were 16 subjects and no indication of the follow up period was given</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-06 13:42:15 +0100" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Carr_x00e3_o-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-06 13:42:15 +0100" MODIFIED_BY="Lindsay Stead">
<P>Buspirone - Pharmacotherapy was combined buspirone and sertraline, vs placebo, as adjunct to cognitive behavioural therapy. Effect of buspirone could not be separated.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Farebrother-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Propanolol - short follow up<BR/>40mg x3/day for 8 wks vs placebo, subjects advised to try to quit after 1 wk of treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gawin-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Buspirone - open trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hatsukami-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Granisetron - short-term study of withdrawal symptoms during 15 days of abstinence</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hilleman-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Buspirone - short follow up<BR/>15mg/day for 1 wk, 30mg/day for 3 wks. Abstinence at 7 days post-cessation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-06 13:42:24 +0100" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Ionescu-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-06 13:42:24 +0100" MODIFIED_BY="Lindsay Stead">
<P>Buspirone - Pharmacotherapy was combined buspirone and sertraline, vs placebo, as adjunct to cognitive behavioural therapy. Effect of buspirone could not be separated.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Robinson-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Buspirone - case series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Robinson-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Buspirone - short follow up<BR/>Buspirone 30mg/day beginning 3 wks before abrupt cessation. Abstinence assessed 2 wks after quit day.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-West-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Buspirone - short follow up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-West-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ondansetron - short follow up<BR/>0.25 mg/day 2 wks before and 4 wks after quit date<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zacny-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ondansetron - Crossover trial of smoking behaviour in an inpatient laboratory</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2009-10-06 14:41:44 +0100" MODIFIED_BY="Lindsay Stead">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2009-10-06 14:41:44 +0100" MODIFIED_BY="Lindsay Stead" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-06 14:37:55 +0100" MODIFIED_BY="Lindsay Stead" RESULT="UNKNOWN" STUDY_ID="STD-Cinciripini-1995--L">
<DESCRIPTION>
<P>Randomly assigned 'balanced on sex ratio and screening level of cotinine'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-06 14:39:36 +0100" MODIFIED_BY="Lindsay Stead" RESULT="UNKNOWN" STUDY_ID="STD-Cinciripini-1995-H">
<DESCRIPTION>
<P>See Cinciripini 1995 L</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-06 14:40:30 +0100" MODIFIED_BY="Lindsay Stead" RESULT="UNKNOWN" STUDY_ID="STD-Dow-1984">
<DESCRIPTION>
<P>Randomized, method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-06 14:40:40 +0100" MODIFIED_BY="Lindsay Stead" RESULT="UNKNOWN" STUDY_ID="STD-Hao-1988">
<DESCRIPTION>
<P>Randomized, method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-06 14:40:52 +0100" MODIFIED_BY="Lindsay Stead" RESULT="UNKNOWN" STUDY_ID="STD-Hilleman-1994">
<DESCRIPTION>
<P>Randomized, method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-06 14:41:05 +0100" MODIFIED_BY="Lindsay Stead" RESULT="UNKNOWN" STUDY_ID="STD-Schneider-1996">
<DESCRIPTION>
<P>Randomized, method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-06 14:41:44 +0100" MODIFIED_BY="Lindsay Stead" RESULT="UNKNOWN" STUDY_ID="STD-Schwartz-1968">
<DESCRIPTION>
<P>Randomized, stratified by social class, method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-10-06 14:41:23 +0100" MODIFIED_BY="Lindsay Stead" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-06 14:38:48 +0100" MODIFIED_BY="Lindsay Stead" RESULT="UNKNOWN" STUDY_ID="STD-Cinciripini-1995--L">
<DESCRIPTION>
<P>No details given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-06 14:39:37 +0100" MODIFIED_BY="Lindsay Stead" RESULT="UNKNOWN" STUDY_ID="STD-Cinciripini-1995-H">
<DESCRIPTION>
<P>See Cinciripini 1995 L</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-06 14:40:09 +0100" MODIFIED_BY="Lindsay Stead" RESULT="UNKNOWN" STUDY_ID="STD-Dow-1984">
<DESCRIPTION>
<P>No details given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-06 14:40:40 +0100" MODIFIED_BY="Lindsay Stead" RESULT="UNKNOWN" STUDY_ID="STD-Hao-1988">
<DESCRIPTION>
<P>No details given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-06 14:40:52 +0100" MODIFIED_BY="Lindsay Stead" RESULT="UNKNOWN" STUDY_ID="STD-Hilleman-1994">
<DESCRIPTION>
<P>No details given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-06 14:41:05 +0100" MODIFIED_BY="Lindsay Stead" RESULT="UNKNOWN" STUDY_ID="STD-Schneider-1996">
<DESCRIPTION>
<P>No details given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-06 14:41:23 +0100" MODIFIED_BY="Lindsay Stead" RESULT="UNKNOWN" STUDY_ID="STD-Schwartz-1968">
<DESCRIPTION>
<P>No details given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2011-06-22 09:53:47 +0100" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2009-10-06 14:10:24 +0100" MODIFIED_BY="Lindsay Stead">
<COMPARISON ID="CMP-001" MODIFIED="2009-10-06 13:46:24 +0100" MODIFIED_BY="Lindsay Stead" NO="1">
<NAME>Buspirone versus placebo/NRT</NAME>
<DICH_OUTCOME CHI2="1.9607376459055146" CI_END="1.331345484395494" CI_START="0.6672310346317871" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9425046551638688" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="62" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.12429076959706707" LOG_CI_START="-0.17572376174700233" LOG_EFFECT_SIZE="-0.025716496074967603" METHOD="MH" MODIFIED="2009-10-06 13:46:24 +0100" MODIFIED_BY="Lindsay Stead" NO="1" P_CHI2="0.5805956399925478" P_Q="0.34411207108784214" P_Z="0.7368660167147907" Q="0.8950518896764692" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="170" TOTAL_2="239" WEIGHT="200.0" Z="0.33600643201977043">
<NAME>Long term abstinence</NAME>
<GROUP_LABEL_1/>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.06270705349544" CI_END="1.3676905016321708" CI_START="0.42149671515300496" DF="2" EFFECT_SIZE="0.7592608601685757" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="20" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.1359878308339891" LOG_CI_START="-0.3752058056097792" LOG_EFFECT_SIZE="-0.11960898738789505" NO="1" P_CHI2="0.58780891444866" P_Z="0.35904624961465137" STUDIES="3" TAU2="0.0" TOTAL_1="102" TOTAL_2="99" WEIGHT="100.00000000000001" Z="0.9171839819385831">
<NAME>Buspirone vs placebo</NAME>
<DICH_DATA CI_END="1.716025295094918" CI_START="0.31944131608380755" EFFECT_SIZE="0.7403846153846154" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.234523685283768" LOG_CI_START="-0.495608913536365" LOG_EFFECT_SIZE="-0.13054261412629847" ORDER="12178" O_E="0.0" SE="0.42888350276159953" STUDY_ID="STD-Cinciripini-1995--L" TOTAL_1="26" TOTAL_2="22" VAR="0.18394105894105894" WEIGHT="42.54530859242335"/>
<DICH_DATA CI_END="1.6592381003098393" CI_START="0.13885891359231448" EFFECT_SIZE="0.48" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.21990871166089082" LOG_CI_START="-0.8574262369097164" LOG_EFFECT_SIZE="-0.3187587626244128" ORDER="12179" O_E="0.0" SE="0.6328318816843779" STUDY_ID="STD-Cinciripini-1995-H" TOTAL_1="25" TOTAL_2="28" VAR="0.4004761904761905" WEIGHT="32.41841365895829"/>
<DICH_DATA CI_END="3.5342513741274257" CI_START="0.3761117180663386" EFFECT_SIZE="1.1529411764705881" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5482974355255733" LOG_CI_START="-0.42468313556916903" LOG_EFFECT_SIZE="0.06180714997820209" ORDER="12180" O_E="0.0" SE="0.5715336037925554" STUDY_ID="STD-Schneider-1996" TOTAL_1="51" TOTAL_2="49" VAR="0.32665066026410566" WEIGHT="25.03627774861836"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6525026774403166" CI_START="0.7037896163045501" DF="0" EFFECT_SIZE="1.0784313725490196" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="42" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.21814217181674783" LOG_CI_START="-0.15255714502413295" LOG_EFFECT_SIZE="0.032792513396307454" NO="2" P_CHI2="1.0" P_Z="0.7287704240812782" STUDIES="1" TAU2="0.0" TOTAL_1="68" TOTAL_2="140" WEIGHT="100.0" Z="0.34676160596701666">
<NAME>Buspirone vs nicotine patch</NAME>
<DICH_DATA CI_END="1.6525026774403166" CI_START="0.7037896163045501" EFFECT_SIZE="1.0784313725490196" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="42" LOG_CI_END="0.21814217181674783" LOG_CI_START="-0.15255714502413295" LOG_EFFECT_SIZE="0.032792513396307454" ORDER="12181" O_E="0.0" SE="0.21775061370354606" STUDY_ID="STD-Hilleman-1994" TOTAL_1="68" TOTAL_2="140" VAR="0.04741532976827094" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2009-10-06 13:50:41 +0100" MODIFIED_BY="Lindsay Stead" NO="2">
<NAME>Diazepam versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-10-06 13:50:41 +0100" MODIFIED_BY="Lindsay Stead" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="38" TOTAL_2="38" WEIGHT="0.0" Z="0.0">
<NAME>Continuous abstinence (6m)</NAME>
<GROUP_LABEL_1/>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8016908099007523" CI_START="0.5550341903864658" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="0.2556802632938584" LOG_CI_START="-0.2556802632938584" LOG_EFFECT_SIZE="0.0" ORDER="12182" O_E="0.0" SE="0.3003757045930553" STUDY_ID="STD-Hao-1988" TOTAL_1="38" TOTAL_2="38" VAR="0.09022556390977443" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2009-10-06 14:10:06 +0100" MODIFIED_BY="Lindsay Stead" NO="3">
<NAME>Meprobamate versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-10-06 14:10:06 +0100" MODIFIED_BY="Lindsay Stead" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="108" TOTAL_2="108" WEIGHT="0.0" Z="0.0">
<NAME>Reduction of &gt;85% at 12 month f/up</NAME>
<GROUP_LABEL_1/>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="9" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>Prescription only</NAME>
<DICH_DATA CI_END="1.131608416473186" CI_START="0.0981886573956424" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.053696168914211494" LOG_CI_START="-1.0079386783535365" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="12183" O_E="0.0" SE="0.6236095644623235" STUDY_ID="STD-Schwartz-1968" TOTAL_1="36" TOTAL_2="36" VAR="0.38888888888888884" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="11" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>Prescription and individual counselling</NAME>
<DICH_DATA CI_END="1.1763128615364855" CI_START="0.1756433828140418" EFFECT_SIZE="0.45454545454545453" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" LOG_CI_END="0.07052284552262186" LOG_CI_START="-0.7553682071670343" LOG_EFFECT_SIZE="-0.3424226808222062" ORDER="12184" O_E="0.0" SE="0.48513249257654895" STUDY_ID="STD-Schwartz-1968" TOTAL_1="36" TOTAL_2="36" VAR="0.23535353535353531" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="10" I2="0.0" ID="CMP-003.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>Prescription and group counselling</NAME>
<DICH_DATA CI_END="1.6348731149512787" CI_START="0.29971744933526695" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.2134840520330931" LOG_CI_START="-0.5232879720045794" LOG_EFFECT_SIZE="-0.1549019599857432" ORDER="12185" O_E="0.0" SE="0.4327835340000672" STUDY_ID="STD-Schwartz-1968" TOTAL_1="36" TOTAL_2="36" VAR="0.1873015873015873" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2009-10-06 14:10:24 +0100" MODIFIED_BY="Lindsay Stead" NO="4">
<NAME>Beta-blockers versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-10-06 14:10:24 +0100" MODIFIED_BY="Lindsay Stead" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="68" TOTAL_2="62" WEIGHT="0.0" Z="0.0">
<NAME>Long term abstinence</NAME>
<GROUP_LABEL_1/>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="1" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2008-05-08 15:24:18 +0100" MODIFIED_BY="L S" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Oxprenolol versus placebo</NAME>
<DICH_DATA CI_END="41.74055009814727" CI_START="0.6765994359598722" EFFECT_SIZE="5.314285714285714" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.6205581683282755" LOG_CI_START="-0.1696683685929942" LOG_EFFECT_SIZE="0.7254448998676407" ORDER="12186" O_E="0.0" SE="1.0515879295518322" STUDY_ID="STD-Dow-1984" TOTAL_1="35" TOTAL_2="31" VAR="1.1058371735791093" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="1" I2="0.0" ID="CMP-004.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2008-05-08 15:24:29 +0100" MODIFIED_BY="L S" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Metoprolol versus placebo</NAME>
<DICH_DATA CI_END="56.66448979886487" CI_START="0.9967000937651689" EFFECT_SIZE="7.515151515151516" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.7533109827791955" LOG_CI_START="-0.001435500882538312" LOG_EFFECT_SIZE="0.8759377409483288" ORDER="12187" O_E="0.0" SE="1.0307467706380848" STUDY_ID="STD-Dow-1984" TOTAL_1="33" TOTAL_2="31" VAR="1.0624389051808407" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2011-06-22 09:53:41 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2011-06-22 09:53:41 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2011-06-22 09:53:36 +0100" MODIFIED_BY="[Empty name]">Glossary of terms</TITLE>
<APPENDIX_BODY MODIFIED="2011-06-22 09:53:41 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="2" ROWS="27">
<TR>
<TH>
<P>Term</P>
</TH>
<TH>
<P>Definition</P>
</TH>
</TR>
<TR>
<TD>
<P>Abstinence</P>
</TD>
<TD>
<P>A period of being quit, i.e. stopping the use of cigarettes or other tobacco products, May be defined in various ways; see also:<BR/>point prevalence abstinence; prolonged abstinence; continuous/sustained abstinence<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Biochemical verification</P>
</TD>
<TD>
<P>Also called 'biochemical validation' or 'biochemical confirmation':<BR/>A procedure for checking a tobacco user's report that he or she has not smoked or used tobacco. It can be measured by testing levels of nicotine or cotinine or other chemicals in blood, urine, or saliva, or by measuring levels of carbon monoxide in exhaled breath or in blood.<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Bupropion</P>
</TD>
<TD>
<P>A pharmaceutical drug originally developed as an antidepressant, but now also licensed for smoking cessation; trade names Zyban, Wellbutrin (when prescribed as an antidepressant)</P>
</TD>
</TR>
<TR>
<TD>
<P>Carbon monoxide (CO)</P>
</TD>
<TD>
<P>A colourless, odourless highly poisonous gas found in tobacco smoke and in the lungs of people who have recently smoked, or (in smaller amounts) in people who have been exposed to tobacco smoke. May be used for biochemical verification of abstinence.</P>
</TD>
</TR>
<TR>
<TD>
<P>Cessation</P>
</TD>
<TD>
<P>Also called 'quitting'<BR/>The goal of treatment to help people achieve abstinence from smoking or other tobacco use, also used to describe the process of changing the behaviour<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Continuous abstinence</P>
</TD>
<TD>
<P>Also called 'sustained abstinence'<BR/>A measure of cessation often used in clinical trials involving avoidance of all tobacco use since the quit day until the time the assessment is made. The definition occasionally allows for lapses. This is the most rigorous measure of abstinence<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>'Cold Turkey'</P>
</TD>
<TD>
<P>Quitting abruptly, and/or quitting without behavioural or pharmaceutical support.</P>
</TD>
</TR>
<TR>
<TD>
<P>Craving</P>
</TD>
<TD>
<P>A very intense urge or desire [to smoke].<BR/>See: Shiffman et al 'Recommendations for the assessment of tobacco craving and withdrawal in smoking cessation trials'<BR/>Nicotine &amp; Tobacco Research 2004: 6(4): 599-614<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Dopamine</P>
</TD>
<TD>
<P>A neurotransmitter in the brain which regulates mood, attention, pleasure, reward, motivation and movement</P>
</TD>
</TR>
<TR>
<TD>
<P>Efficacy</P>
</TD>
<TD>
<P>Also called 'treatment effect' or 'effect size':<BR/>The difference in outcome between the experimental and control groups<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Harm reduction</P>
</TD>
<TD>
<P>Strategies to reduce harm caused by continued tobacco/nicotine use, such as reducing the number of cigarettes smoked, or switching to different brands or products, e.g. potentially reduced exposure products (PREPs), smokeless tobacco.</P>
</TD>
</TR>
<TR>
<TD>
<P>Lapse/slip</P>
</TD>
<TD>
<P>Terms sometimes used for a return to tobacco use after a period of abstinence. A lapse or slip might be defined as a puff or two on a cigarette. This may proceed to relapse, or abstinence may be regained. Some definitions of continuous, sustained or prolonged abstinence require complete abstinence, but some allow for a limited number or duration of slips. People who lapse are very likely to relapse, but some treatments may have their effect by helping people recover from a lapse.</P>
</TD>
</TR>
<TR>
<TD>
<P>nAChR</P>
</TD>
<TD>
<P>[neural nicotinic acetylcholine receptors]: Areas in the brain which are thought to respond to nicotine, forming the basis of nicotine addiction by stimulating the overflow of dopamine</P>
</TD>
</TR>
<TR>
<TD>
<P>Nicotine</P>
</TD>
<TD>
<P>An alkaloid derived from tobacco, responsible for the psychoactive and addictive effects of smoking.</P>
</TD>
</TR>
<TR>
<TD>
<P>Nicotine Replacement Therapy (NRT)</P>
</TD>
<TD>
<P>A smoking cessation treatment in which nicotine from tobacco is replaced for a limited period by pharmaceutical nicotine. This reduces the craving and withdrawal experienced during the initial period of abstinence while users are learning to be tobacco-free The nicotine dose can be taken through the skin, using patches, by inhaling a spray, or by mouth using gum or lozenges.</P>
</TD>
</TR>
<TR>
<TD>
<P>Outcome</P>
</TD>
<TD>
<P>Often used to describe the result being measured in trials that is of relevance to the review. For example smoking cessation is the outcome used in reviews of ways to help smokers quit. The exact outcome in terms of the definition of abstinence and the length of time that has elapsed since the quit attempt was made may vary from trial to trial.</P>
</TD>
</TR>
<TR>
<TD>
<P>Pharmacotherapy</P>
</TD>
<TD>
<P>A treatment using pharmaceutical drugs, e.g. NRT, bupropion</P>
</TD>
</TR>
<TR>
<TD>
<P>Point prevalence abstinence (PPA)</P>
</TD>
<TD>
<P>A measure of cessation based on behaviour at a particular point in time, or during a relatively brief specified period, e.g. 24 hours, 7 days. It may include a mixture of recent and long-term quitters. cf. prolonged abstinence, continuous abstinence</P>
</TD>
</TR>
<TR>
<TD>
<P>Prolonged abstinence</P>
</TD>
<TD>
<P>A measure of cessation which typically allows a 'grace period' following the quit date (usually of about two weeks), to allow for slips/lapses during the first few days when the effect of treatment may still be emerging.<BR/>See: Hughes et al 'Measures of abstinence in clinical trials: issues and recommendations'; Nicotine &amp; Tobacco Research, 2003: 5 (1); 13-25<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Relapse</P>
</TD>
<TD>
<P>A return to regular smoking after a period of abstinence</P>
</TD>
</TR>
<TR>
<TD>
<P>Secondhand smoke</P>
</TD>
<TD>
<P>Also called passive smoking or environmental tobacco smoke [ETS]<BR/>A mixture of smoke exhaled by smokers and smoke released from smouldering cigarettes, cigars, pipes, bidis, etc. The smoke mixture contains gases and particulates, including nicotine, carcinogens and toxins.<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Self-efficacy</P>
</TD>
<TD>
<P>The belief that one will be able to change one's behaviour, e.g. to quit smoking</P>
</TD>
</TR>
<TR>
<TD>
<P>SPC [Summary of Product Characteristics]</P>
</TD>
<TD>
<P>Advice from the manufacturers of a drug, agreed with the relevant licensing authority, to enable health professionals to prescribe and use the treatment safely and effectively.</P>
</TD>
</TR>
<TR>
<TD>
<P>Tapering</P>
</TD>
<TD>
<P>A gradual decrease in dose at the end of treatment, as an alternative to abruptly stopping treatment</P>
</TD>
</TR>
<TR>
<TD>
<P>Titration</P>
</TD>
<TD>
<P>A technique of dosing at low levels at the beginning of treatment, and gradually increasing to full dose over a few days, to allow the body to get used to the drug. It is designed to limit side effects.</P>
</TD>
</TR>
<TR>
<TD>
<P>Withdrawal</P>
</TD>
<TD>
<P>A variety of behavioural, affective, cognitive and physiological symptoms, usually transient, which occur after use of an addictive drug is reduced or stopped.<BR/>See: Shiffman et al 'Recommendations for the assessment of tobacco craving and withdrawal in smoking cessation trials'<BR/>Nicotine &amp; Tobacco Research 2004: 6(4): 599-614<BR/>
</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>